Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies

Journal of Investigative Dermatology

Volumn 114, Issue 2, 2000, Pages 277-280

  Birck, Anette ^a,b   Ahrenkiel, Vibeke ^a   Zeuthen, Jesper ^a   Hou Jensen, Klaus ^b   Guldberg, Per ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b Illinois   (Denmark)

Author keywords

Loss of heterozygosity; Tumor suppressor

Indexed keywords

GENE PRODUCT; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CHROMOSOME 10Q; COWDEN SYNDROME; GENE MUTATION; HAMARTOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0034086867     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2000.00877.x     Document Type: Article

References (37)

1. Bastian BC, LeBoit PE, Hamm H, Bröcker EG. Pinkel D: Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 58:2170-2175, 1998
2. Böni R, Vortmeyer AO, Burg G, Hofbauer G, Zhuang Z: The PTEN tumour suppressor gene and malignant melanoma. Melanoma Res 8:300-302, 1998
3. Cairns P, Mao L, Merlo A, et al. Rates of (MTS1) mutations in primary tumors with 9p loss. Science 265:415-417, 1994
4. Cairns P, Okami K, Halachmi S, et al: Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57:4997-5000, 1997
5. Cheney IW, Johnson DE, Vaillancourt MT, et al. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res 58:2331-2334, 1998
6. Cremonesi L, Firpo S, Ferrari M, Righetti PG, Gelfi C: Double-gradient DGGE for optimized detection of DNA point mutations. Biotechniques 22:326-330, 1997
7. Dahia PL, Marsh DJ, Zheng Z, et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57:4710-4713, 1997
8. Davies MA, Lu Y, Sano T, et al: Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 58:5285-5290, 1998
9. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP: Pten is essential for embryonic development and tumour suppression. Nat Genet 19:348-355, 1998
10. Frisch SM, Ruoslahti E: Integrins and anoikis. Curr Opin Cell Biol 9:701-706, 1997
11. Furnari FB, Lin H, Huang HS, Cavenee WK: Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA 94:12479-12484, 1997
12. Furnari FB, Huang HJ, Cavenee WK: The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res 58:5002-5008, 1998
13. Giambernardi TA, Rodeck U, Klebe RJ: Bovine serum albumin reverses inhibition of RT-PCR by melanin. Biotechniques 25:564-566, 1998
14. Guldberg P, Thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J: Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57:3660-3663, 1997
15. Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D: Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 8:1195-1198, 1998
16. Healy E, Rehman I, Angus B, Rees JL: Loss of heterozygosity in sporadic primary cutaneous melanoma. Cenes Chromosomes Cancer 12:152-156, 1995
17. Healy E, Belgaid CE, Takata M, Vahlquist A, Rehman I, Rigby H, Rees JL: Allelotypes of primary cutaneous melanoma and benign melanocytic nevi. Cancer Res 56:589-593, 1996
18. Isshiki K, Elder DE, Guerry D, Linnenbach AJ: Chromosome 10 allelic loss in malignant melanoma. Genes Chromosomes Cancer 8:178-184, 1993
19. Kong D, Suzuki A, Zou TT, et al: PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Getnet 17:143-144, 1997
20. Li J, Yen C, Liaw D, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer, Science 275:1943-1947, 1997
21. Liaw D, Marsh DJ, Li J. ct al: Gennline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16:64-67, 1997
22. Maehama T, Dixon JE: The tumor suppressor. PTEN/MMAC1, dephosphorylates the lipid second messenger. phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273:13375-13378, 1998
23. Marsh DJ, Dahia PLM, Zheng Z, Liaw D, Parsons R, Gorlin RJ, Eng C: Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 16:333-334, 1997
24. Myers MP, Pass I, Batty IH, et al. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc Natl Acad Sci USA 95:13513-13518, 1998
25. Nelen MR, van Staveren WCG, Peeters EAJ, et al: Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 6:1383-1387, 1997.
26. Risinger JI, Hayes AK, Berchuck A, Barrett JC: PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57:4736-4738, 1997
27. Robertson GP, Furnari FB, Miele ME. et al: In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc Natl Acad Sci USA 95:9418-9423, 1998
28. Sheffield VC, Cox DR, Lerman LS, Myers RM: Attachment of a 40-base-pair G+C rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction in improved detection of single-base changes. Proc Natl Acad Sci USA 86:232-236, 1989
29. Stambolic V, Suzuki A, de la Pompa JL, et al: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:29-39, 1998
30. Steck PA, Pershouse MA, Jasser SA, et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356-362, 1997
31. Suzuki A, de la Pompa JL, Stambolic V, et al: High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 8:1169-1178, 1998
32. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM: Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN, Science 280:1614-1617, 1998
33. Teng DH, Hu R, Lin H, et al: MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57:5221-5225, 1997
34. Thompson FH, Emerson J, Oison S, et al: Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. Cancer Genet Cytogenet 83:93-104, 1995
35. Tsao H, Zhang X, Benoit E, Haluska FG: Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 16:3397-3402, 1998
36. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J: Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58:2720-2723, 1998
37. Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, Parsons R: Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57:4183-4186, 1997